About this trial
The assessment of AI -based prediction models in detecting AKI early in critically ill patients. Specifically, the aim is to evaluate the model's ability to predict the onset of AKI before it clinically manifests allowing for early interventions
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All adult (aged 18 years old and older) patients who were admitted to the ICU were included in this study.
Disqualifiers
• patients under 18 years old
End-stage renal disease
Acute Kidney Injury at ICU admission
Inability to obtain sufficient clinical data
Trial population
Baseline characteristics, including demographic information, comorbidities, vital signs, laboratory results, medical interventions, disease severity scores, etc. were carefully reviewed and collected. The definitions of comorbidities including congestive heart failure, peptic ulcer disease, myocardial infarction, peripheral vascular disease, diabetes, dementia, chronic pulmonary disease, rheumatic disease, cerebrovascular disease, cancer, paraplegia, liver disease, renal disease, and acquired immunedeficiency syndrome. Severe organ failure due to ineffective immune response to infection was identified as sepsis. During the first 24 h when the patient was admitted to the ICU, the average values of the patient's vital signs (heart rate, mean arterial pressure, respiration rate, body temperature, and SpO2) were measured,, and the highest value of the biochemical laboratory tests (hematocrit, hemoglobin, platelets, white blood cell, blood urea nitrogen, international normalized ratio, Scr,
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
The assessment of AI -based prediction models in detecting AKI early in critically ill patients.
assessment of the ability of the AI based model to detect AKI in critically ill patients by evaluating the model ability to predict the onset of early AKI before it is clinically manifested for early interventions . this will be done by generating an AKI risk score by the model for each patient. Outcomes are tracked and the model is updated periodically based on new patient data to improve accuracy and reliability
Secondary outcomes
assessment of other aspects
assessment of clinical outcomes ( e.g, time to intervention , AKI severity , RRT use, and patient mortality ) impact on ICU (length of ICU stay)
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: